BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

HanchorBio Licenses Novel CD47 Fusion Protein HCB101 to Henlius in $200 Million+ Regional Deal

HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, annou...

July 02, 2025 | News

Mabwell Grants Qilu Pharmaceutical Greater China Rights to Next-Generation Long-Acting G-CSF Albipagrastim Alfa

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an ag...

June 30, 2025 | News

Taiwan’s Brain Navi Secures US FDA Clearance for NaoTrac Robotic Neurosurgical System

Brain Navi Biotechnology, a medical robotics company founded in 2015 in Taiwan by surgeon and serial entrepreneur Jerry Chen, has reached another majo...

June 18, 2025 | News

Harrow Secures Exclusive U.S. Rights to BYQLOVI for Post-Surgical Eye Care Following FDA Approval

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today a...

June 10, 2025 | News

AnnJi Reports Promising Phase 1/2a Results for AJ201 in Rare Neuromuscular Disease SBMA

AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and r...

May 22, 2025 | News

Gene Solutions and NEWCL Partner to Launch Advanced NGS Laboratory in Taiwan for Prenatal and Oncology Genetic Testing

Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan's pioneering clinical laboratory ...

May 19, 2025 | News

Taiwan’s Formosa Pharmaceuticals Partners with Apotex to Commercialize APP13007 in Mexico for Post-Ocular Surgery Treatment

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), ...

May 07, 2025 | News

China Grants Full Approval to Everest Medicines’ NEFECON® as First and Only Etiological Treatment for IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

May 07, 2025 | Regulatory

Primo Biotechnology Secures PIC/S GMP and GDP Certifications, Strengthening Global Position in Nuclear Medicine

Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Dr...

April 25, 2025 | News

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

TCI Biotech Elevates CDMO+ Services with US-Based Glass Bottling for Liquid Supplements

TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling s...

April 03, 2025 | News

AnHorn Medicines Doses First Subject in U.S. Phase I Trial for AH-001, a First-in-Class Protein Degrader Targeting Hair Loss

AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class protein degrader for androg...

March 27, 2025 | News

TPIsoftware & Yuan's General Hospital Transform Healthcare with GenAI Platform

TPIsoftware (TWSE: 7781) and Yuan's General Hospital, a leading medical institution in Southern Taiwan, have collaborated to launch a digit...

March 20, 2025 | News

Formosa Pharmaceuticals and Cipla Sign Multi-Regional Licensing Deal for Ophthalmic Suspension APP13007

Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clob...

March 19, 2025 | News

Stay Connected